One more point about RHEO: a sham rheopheresis procedure—which is what patients in the placebo arm of RHEO’s trial received—is not going to make someone read an eye chart better. Thus, the claim in RHEO’s PR that an unexpectedly good response in the placebo arm caused the trial’s demise is patently absurd.
Market Data 
Markets 
AI
